Blood pressure in early autosomal dominant polycystic kidney disease

New England Journal of Medicine

Volumn 372, Issue 10, 2015, Pages 975-977

  Messchendorp, A Lianne ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE REGULATION; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY POLYCYSTIC DISEASE; LETTER; NEPHRON; PRIORITY JOURNAL; TREATMENT PLANNING; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; HEART LEFT VENTRICLE MASS; MONOTHERAPY; PATIENT SAFETY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SURVIVAL RATE; URINARY EXCRETION; FEMALE; HYPERTENSION; KIDNEY; MALE; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

ALBUMIN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; LISINOPRIL;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; LISINOPRIL; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 84924447921     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1500332     Document Type: Letter

References (3)

1. Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 2014;371: 2255-66.
2. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014;64: 821-35.
3. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148-57.